PharmGKB Summary: Ondansetron and Tropisetron Pathways, Pharmacokinetics and Pharmacodynamics

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2019 Jan 24

PMID 30672837

Citations 6

Authors

Rachel Huddart

Russ B Altman

Teri E Klein

Affiliations

Soon will be listed here.

Citing Articles

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.

Lam K, Mondick J, Peltz G, Wu M, Kraft W Clin Transl Sci. 2025; 18(2):e70147.

PMID: 39930952 PMC: 11811511. DOI: 10.1111/cts.70147.

The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets.

Lam K, Peltz G, Kraft W Expert Opin Investig Drugs. 2025; 34(1-2):49-59.

PMID: 39900407 PMC: 11899659. DOI: 10.1080/13543784.2025.2462615.

CYP2D6 genotype and associated 5-HT receptor antagonist outcomes: A systematic review and meta-analysis.

Moore C, Williams E, Dyas R, Halman A, Stenta T, Khatri D Clin Transl Sci. 2025; 18(2):e70108.

PMID: 39899439 PMC: 11789932. DOI: 10.1111/cts.70108.

Effect of Prophylactic Tropisetron on Post-Operative Nausea and Vomiting in Patients Undergoing General Anesthesia: Systematic Review and Meta-Analysis with Trial Sequential Analysis.

Kim I, Choi G, Hwang H, Kang H J Pers Med. 2024; 14(8).

PMID: 39201989 PMC: 11355328. DOI: 10.3390/jpm14080797.

A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients.

Alqahtani F, Alruwaili A, Alasmari M, Almazroa S, Alsuhaibani K, Rasool M Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139819 PMC: 10747545. DOI: 10.3390/ph16121693.

References

Edginton A, Schmitt W, Voith B, Willmann S . A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006; 45(7):683-704. DOI: 10.2165/00003088-200645070-00004. View

Apfel C, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I . A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004; 350(24):2441-51. PMC: 1307533. DOI: 10.1056/NEJMoa032196. View

Deng P, Zhong D, Chen X . Determination of tropisetron in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2009; 49(3):848-52. DOI: 10.1016/j.jpba.2008.12.038. View

Silva S, Hu L, Sousa J, Pais A, Michniak-Kohn B . A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl. Eur J Pharm Biopharm. 2011; 80(3):663-73. DOI: 10.1016/j.ejpb.2011.11.010. View

Rojas C, Thomas A, Alt J, Stathis M, Zhang J, Rubenstein E . Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2009; 626(2-3):193-9. DOI: 10.1016/j.ejphar.2009.10.002. View

Fischer V, Vickers A, Heitz F, Mahadevan S, Baldeck J, Minery P . The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994; 22(2):269-74. View

Kuryshev Y, Brown A, Wang L, Benedict C, Rampe D . Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000; 295(2):614-20. View

Abali H, Celik I . Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Invest. 2007; 25(3):135-9. DOI: 10.1080/07357900701208709. View

Zhu Y, Zhang Q, Zou J, Wan M, Zhao Z, Zhu J . Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. Drug Des Devel Ther. 2015; 9:4621-9. PMC: 4541558. DOI: 10.2147/DDDT.S86415. View

10.

Cubeddu L, Hoffmann I, Fuenmayor N, Finn A . Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990; 322(12):810-6. DOI: 10.1056/NEJM199003223221204. View

11.

Paul M, Callahan R, Au J, Kindler C, Yost C . Antiemetics of the 5-hydroxytryptamine 3A antagonist class inhibit muscle nicotinic acetylcholine receptors. Anesth Analg. 2005; 101(3):715-721. DOI: 10.1213/01.ANE.0000160531.65953.77. View

12.

Stevens A, Woodman R, Owen H . The effect of ondansetron on the efficacy of postoperative tramadol: a systematic review and meta-analysis of a drug interaction. Anaesthesia. 2014; 70(2):209-18. DOI: 10.1111/anae.12948. View

13.

Lee C, Plosker G, McTavish D . Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs. 1993; 46(5):925-43. DOI: 10.2165/00003495-199346050-00009. View

14.

Alusik S, Kalatova D, Paluch Z . Serotonin syndrome. Neuro Endocrinol Lett. 2014; 35(4):265-73. View

15.

Fisher S, Kiley K, Porter N, Stiff P . Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant. 2002; 7(11):596-603. DOI: 10.1053/bbmt.2001.v7.pm11760147. View

16.

Lewis D, Ito Y, Eddershaw P, Dickins M, Goldfarb P . An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6. Drug Metab Lett. 2010; 4(1):25-30. DOI: 10.2174/187231210790980408. View

17.

Van Wijngaarden I, Tulp M, Soudijn W . The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990; 188(6):301-12. DOI: 10.1016/0922-4106(90)90190-9. View

18.

Dychter S, Harrigan R, Bahn J, Printz M, Sugarman B, DeNoia E . Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. Clin Ther. 2014; 36(2):211-24. DOI: 10.1016/j.clinthera.2013.12.013. View

19.

Perwitasari D, Wessels J, van der Straaten R, Baak-Pablo R, Mustofa M, Hakimi M . Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol. 2011; 41(10):1168-76. DOI: 10.1093/jjco/hyr117. View

20.

Gilbert C, Petros W, Vredenburgh J, Hussein A, ROSS M, Rubin P . Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998; 42(6):497-503. DOI: 10.1007/s002800050851. View